Cosunter(SZ:300436) Ge Long Hui A P P·2025-09-01 12:08Core Viewpoint - The company is enhancing its innovative drug development funding and operational capital through a significant equity transfer and capital increase involving its subsidiary, Guangsheng Zhonglin, while relinquishing its preferential rights [1] Group 1: Equity Transfer and Capital Increase - The company approved a proposal to transfer minority shareholder equity and introduce important investors for Guangsheng Zhonglin, with a total transaction amount of 250 million yuan [1] - Jinan Taishen Investment Partnership and Huaxin Shiheng will invest 141.35 million yuan and 50 million yuan respectively, based on a pre-investment valuation of 2.5 billion yuan for Guangsheng Zhonglin [1] - Jinan Taishen will also acquire equity worth 58.65 million yuan from existing shareholders, based on a pre-investment valuation of 1.75 billion yuan [1] Group 2: Changes in Shareholding and Capital Structure - Following the transaction, Guangsheng Zhonglin's registered capital will increase from 388.5 million yuan to 418.236 million yuan [2] - The company's shareholding in Guangsheng Zhonglin will decrease from 81.08% to 75.32%, but Guangsheng Zhonglin will remain a controlled subsidiary, not affecting the scope of the company's consolidated financial statements [2]